Drug Profile
Anti-TNFalpha polyclonal antibody - Advanced Biotherapy
Latest Information Update: 04 Nov 2003
Price :
$50
*
At a glance
- Originator Advanced Biotherapy
- Developer Advanced Biotherapy; Brown University Medical School; Russian Academy of Medical Sciences
- Class
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis